Mach7 Technologies Limited (TDMMF) Shareholder/Analyst Call Transcript

Mach7 Technologies held its 2025 virtual Annual General Meeting, with chairman Rob Bazzani confirming a quorum and introducing executive leadership including CEO Teri Thomas, CFO Dan Lee and Non‑Executive Director Dr. Eliot Siegel; auditors RSM were in attendance. The meeting agenda covers a CEO overview of FY‑25 results and FY‑26 focus, followed by formal resolutions, Q&A and electronic voting; the provided excerpt contains no financial metrics or guidance to evaluate near‑term earnings impact.

Analysis

Market structure: Small-cap enterprise-imaging vendors like Mach7 (OTCPK:TDMMF) stand to gain if FY26 guidance emphasizes recurring SaaS/ARR growth and large-hospital rollouts; winners include software-first integrators and cloud partners, losers are legacy hardware/PACS vendors whose installation revenue is being displaced. Pricing power will improve with network effects once >3 major hospital systems adopt a unified platform (threshold: ~50k imaging studies/month), compressing legacy vendors’ margins over 12–36 months. Cross-asset: expect elevated equity illiquidity and idiosyncratic volatility in TDMMF (options likely thin), negligible commodity impact, modest FX sensitivity via AUD/USD if primary listing is Australian, and potential credit-market ripples only if a material financings occurs.

Risk assessment: Tail risks include a major data-privacy breach, large-client contract loss (>20% of FY revenue), or failure to maintain ASX/OTC listing — each could wipe out >50% value quickly; regulatory certification delays (e.g., CE/FDA) could knock 6–12 months off adoption. Time horizons: immediate (days) = low-news drift; short-term (weeks–months) = reaction to FY26 guidance and cash runway disclosures; long-term (12–24 months) = M&A/takeout or material ARR scale. Hidden dependencies: customer concentration, integration complexity with EHRs, and reseller channel economics; catalysts are new enterprise contracts, certification milestones, or a strategic partnership with GE (GE) / Siemens Healthineers (SHL.DE).

Trade implications: Direct: consider a tactical 1–2% long position in TDMMF (small-cap slot) with a 30% stop-loss and plan to scale to 3–4% if quarterly ARR growth >20% or gross margin expands >500bps within two quarters. Pair: long TDMMF vs short Philips (PHG) or hardware-heavy imaging exposure (size-adjusted) over 12–24 months to capture software secularization; expect 2–4x relative re-rating if thesis holds. Options: if liquid, buy 12–18 month LEAP calls ~25–40% OTM (cost <10% notional) or, where illiquid, buy stock and hedge with 3–6 month protective puts if volatility spikes above 60% implied.

Contrarian angles: Consensus likely underestimates M&A probability — precedent shows strategic acquirers pay 2–4x revenue for niche imaging software; a takeout at mid/high single-digit multiples of revenue would deliver 2–5x equity upside in 12–24 months. Conversely, downside is underappreciated if customer churn >15% or cash runway <12 months, which should trigger exit. Watch for non-linear outcomes: a single marquee contract or breach can change valuation by multiples quickly, so size positions for binary risk.

Key Decisions for Investors

• Establish a 1–2% portfolio long position in Mach7 (OTCPK:TDMMF) within 1–4 weeks post-FY26 guidance, tighten to a 30% stop-loss; scale up to 3–4% only if next two quarters show ARR growth >20% and gross margin improvement >500bps.
• Implement a pair trade: long TDMMF (1–2%) vs short 0.5–1% exposure to hardware-centric imaging vendor Philips (PHG) or similar legacy PACS exposure, horizon 12–24 months, target relative outperformance of 200–400 bps/yr.
• If options liquidity exists, buy 12–18 month LEAP calls on TDMMF ~30% OTM sized to <0.5% portfolio risk, or alternatively buy the stock and hedge with 3–6 month protective puts if implied volatility rises above 60%.
• Reduce direct exposure to hardware-imaging stocks by 1–3% and reallocate into software/health-IT names (e.g., sector picks: Cerner/Oracle (ORCL) healthcare modules, MED tech SaaS ETFs) if Mach7 or peers report sustained ARR acceleration over next two quarters.
• Trigger-based rule: exit all TDMMF exposure immediately if company discloses loss of a customer representing >20% of FY revenue, a cash runway under 12 months absent committed financing, or failure to maintain primary listing — these are binary downside thresholds.